Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
Cardiovascular Diseases
/ epidemiology
Comorbidity
Diabetes Mellitus
/ epidemiology
Female
Hematologic Neoplasms
/ epidemiology
Hospital Mortality
Humans
Leukemia
/ epidemiology
Lymphoma
/ epidemiology
Male
Malnutrition
/ epidemiology
Middle Aged
Multiple Myeloma
/ epidemiology
SARS-CoV-2
/ isolation & purification
Smoking
/ epidemiology
Treatment Outcome
Viral Load
COVID-19
Haematologic malignancies
Mortality
SARS-CoV-2
Super-spreader
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
05
07
2021
accepted:
25
08
2021
pubmed:
15
9
2021
medline:
26
10
2021
entrez:
14
9
2021
Statut:
ppublish
Résumé
Specificities of COVID-19 disease course in patients with haematologic malignancies are still poorly studied. So, we aimed to compare patients with haematologic malignancies to patients without malignancies, matched by sex and age and hospitalised for COVID-19 at the same time and in the same centre. Among 25 patients with haematologic malignancies, we found that mortality (40% versus 4%, p < 0.01), number of days with RT-PCR positivity (21.2 ± 15.9 days [range, 3-57] versus 7.4 ± 5.6 days [range, 1-24], p < 0.01), maximal viral load (mean minimal Ct, 17.2 ± 5.2 [range, 10-30] versus 26.5 ± 5.1 [range, 15-33], p < 0.0001) and the delay between symptom onset and clinical worsening (mean time duration between symptom onset and first day of maximum requirement in inspired oxygen fraction, 14.3 ± 10.7 days versus 9.6 ± 3.7 days, p = 0.0485) were higher than in other patients. COVID-19 course in patients with haematologic malignancies has a delayed onset and is more severe with a higher mortality, and patients may be considered as super-spreaders. Clinicians and intensivists need to be trained to understand the specificity of COVID-19 courses in patients with haematological malignancies.
Identifiants
pubmed: 34518918
doi: 10.1007/s00277-021-04656-z
pii: 10.1007/s00277-021-04656-z
pmc: PMC8437431
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2799-2803Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
COVID-19 pandemic. In: European Centre for Disease Prevention and Control. https://www.ecdc.europa.eu/en/covid-19-pandemic . Accessed 24 Dec 2020
Vijenthira A, Gong IY, Fox TA et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. https://doi.org/10.1182/blood.2020008824
doi: 10.1182/blood.2020008824
pubmed: 33113551
pmcid: 7746126
Passamonti F, Cattaneo C, Arcaini L et al (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7:e737–e745. https://doi.org/10.1016/S2352-3026(20)30251-9
doi: 10.1016/S2352-3026(20)30251-9
pubmed: 32798473
pmcid: 7426107
Shah V, Ko Ko T, Zuckerman M et al (2020) Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience. Br J Haematol 190:e279–e282. https://doi.org/10.1111/bjh.16935
doi: 10.1111/bjh.16935
pubmed: 32526039
Martínez-López J, Mateos M-V, Encinas C et al (2020) Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J 10:103. https://doi.org/10.1038/s41408-020-00372-5
doi: 10.1038/s41408-020-00372-5
pubmed: 33077708
pmcid: 7570395
Cattaneo C, Daffini R, Pagani C et al (2020) Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer 126:5069–5076. https://doi.org/10.1002/cncr.33160
doi: 10.1002/cncr.33160
pubmed: 32910456
Hu B, Guo H, Zhou P, Shi Z-L (2020) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 1–14. https://doi.org/10.1038/s41579-020-00459-7
Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Heart Lung Transplant 39:405–407. https://doi.org/10.1016/j.healun.2020.03.012
doi: 10.1016/j.healun.2020.03.012
pubmed: 32362390
pmcid: 7118652
Manrubia SC, Escarmís C, Domingo E, Lázaro E (2005) High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene 347:273–282. https://doi.org/10.1016/j.gene.2004.12.033
doi: 10.1016/j.gene.2004.12.033
pubmed: 15777632
Martinot M, Jary A, Fafi-Kremer S et al (2020) Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1474
doi: 10.1093/cid/ciaa1474